Tag Archives: Clinical Trial

This Is Why PTSD Cannabis Research Needs the VA Secretary's Help Right Now

This Is Why PTSD Cannabis Research Needs the VA Secretary’s Help Right Now

This Is Why PTSD Cannabis Research Needs the VA Secretary’s Help Right Now

On Aug. 6, 2017, Sue Sisley, M.D., sent a letter to Secretary of Veterans Affairs David Shulkin to request that he stop a Phoenix hospital’s obstruction of the first clinical trial to study the effects of medical cannabis in the treatment of post-traumatic stress disorder in military veterans.

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.

5 Drug-Developing Marijuana Stocks You Need to Know

5 Drug-Developing Marijuana Stocks You Need to Know

Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.

SeeThruEquity RSHO Raúl Elizalde

Medical Marijuana, Inc. Investment Axim Biotech Announces Enrolled Patients Begin Phase II Trial for the Treatment of Irritable Bowel Syndrome (IBS) with CanChew Plus Cannabidiol (CBD) Chewing Gum

NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.

Science and Medicine of Cannabis: Coping With PTSD

Science and Medicine of Cannabis: Coping With PTSD

Sue Sisley, M.D., is leading the way in studying medical marijuana and post-traumatic stress disorder. In her talk, “Coping With PTSD,” hear Sisley discuss the first clinical trial to study the effects of medical marijuana in the treatment of post-traumatic stress disorder in military veterans.

PTSD Marijuana Study Dispenses MMJ to First Military Veteran

PTSD Marijuana Study Dispenses MMJ to First Military Veteran

On Feb. 6, 2017, the first clinical trial to study the effects of medical marijuana in the treatment of post-traumatic stress disorder in military veterans dispensed medical marijuana to its first veteran at the Scottsdale Research Institute in Phoenix.

MJIN_MAPS-Logo-Web

First Participant Enrolled in First-Ever Trial of Marijuana for Chronic PTSD in Veterans

PHOENIX, Ariz., Feb. 7, 2017 /Weed Wire/ — On February 6, 2017, the first participant in the first-ever clinical trial of smoked marijuana (cannabis) for post-traumatic stress disorder (PTSD) in U.S. veterans received cannabis at the Scottsdale Research Institute (SRI) in Phoenix, Ariz.

Cannabis & Parkinson's Disease Study Preps for Launch

Cannabis & Parkinson’s Disease Study Preps for Launch

On Oct. 2, 2016, Maureen Leehey, MD, discussed the potential of cannabis in treating Parkinson’s disease at the 3rd Annual Parkinson’s Disease Symposium at the University of Colorado Movement Disorders Center.

Osteoarthritis

First Health Canada-Approved Medical Cannabis Trial Targets Osteoarthritis

The first Health Canada-approved clinical trial for medical cannabis has started patient recruitment to determine the pain-relieving characteristics of vaporized cannabis.

Columbia Care Announces Agreement with Mount Sinai to Drive Medical Marijuana Research

NEW YORK, June 24, 2015 /PRNewswire/ — Columbia Care LLC, one of the nation’s leading medical marijuana companies, announced a research agreement today with the Icahn School of Medicine at Mount Sinai, an internationally acclaimed research institution in New York City, to advance the science and safe practice of medical marijuana therapy. The agreement funds ongoing retrospective research already underway. The two institutions are also discussing the formation of the New York State Medical Marijuana Research Network (MMRN), which will develop a registry research project to explore the safety and efficacy of medical marijuana in treating a range of clinical conditions.


Top